PX-3
From Wikipedia, the free encyclopedia
 |
|
| Systematic (IUPAC) name | |
|---|---|
|
N-(2-amino-1-benzyl-2-oxo-ethyl)-1-(cyclohexylmethyl)indazole-3-carboxamide
|
|
| Clinical data | |
| Legal status |
|
| Identifiers | |
| CAS Number | 1185887-14-2 |
| PubChem | CID 70969676 |
| Chemical data | |
| Formula | C24H28N4O2 |
| Molar mass | 404.5 g/mol |
|
|
|
PX-3 (also known as APP-CHMINACA) is an indazole-based synthetic cannabinoid. It is a potent agonist of the CB1 receptor with a binding affinity of Ki = 47.6 nM and was originally developed by Pfizer in 2009 as an analgesic medication.[1][2][3]
The acronym 'APP' signifies the 'amino', 'phenyl' and 'propanone' elements of the structure. Three related compounds, PX-1 (5F-APP-PICA, SRF-30), PX-2 (5F-APP-PINACA, FU-PX) and APP-FUBINACA were reported by the EMCDDA in late 2014.[4][5]
Legality[edit]
Sweden's public health agency suggested to classify APP-CHMINACA as hazardous substance on June 1, 2015.[6]
See also[edit]
References[edit]
- ^ "APP-CHMINACA". Cayman Chemical. Retrieved 24 June 2015.
- ^ "Patent WO/2009/106980 - Indazole derivatives".
- ^ "EWS Forum - In Belgien wurde die neue psychoaktive Substanz N-(2-amino-1-benzyl-2-oxo-ethyl)-1-(cyclohexylmethyl)indazole-3-carboxamide (APP-CHMINACA) identifiziert.". Retrieved 24 June 2015.
- ^ "EWS Forum - In Schweden wurde die neue psychoaktive Substanz N-(1-amino-1-oxo-3-phenylpropan-2-yl)-1-(5-fluoropentyl)-1H-indole-3-carboxamide (5F-APP-PICA) identifiziert.". Retrieved 24 June 2015.
- ^ "EWS Forum - In Schweden wurden folgende drei neue psychoaktive Substanzen identifiziert.". Retrieved 24 June 2015.
- ^ "23 nya ämnen kan klassas som narkotika eller hälsofarlig vara". Folkhälsomyndigheten. Retrieved 29 June 2015.
|
 |
This cannabinoid related article is a stub. You can help Wikipedia by expanding it. |
